Statement

SI. No	Name of the Formulation	Strength	Pack size	Ceiling Price (Rs.)
1.	Rifampicin Capsules	150mg/Capsule	4's Bottle/Strip	4.25
2.	Rifampicin Capsules	ISOmg/Capsules	I2's Bottle/Strip	12.72
3.	Rifampicin Capsules	ISOmg/Capsules	100's Bottle	103 46
4.	Rifampicin Capsules	300mg/Capsule	4's Bottle/Strip	7.82
5,	Rifampicin Capsules	300mg/Capsule	100's Bottle	192.83
6.	Rifampicin Capsules	450mg/Capsule	3's Bottle/Strip	8.70
7.	Rifampicin and Isoniazid Capsules	Rifampicin 450mg and Isoniazid 300mg per Capsule	3's Strip/Bottle	9.00
8.	Rifampicin and Isoniazid Capsules	Rifampicin 450mg and Isoniazid 300mg per Capsule	4's Strip/Bottle	12-01
9,	Rifampicin and Isoniazid Capsules	Rifampicin 450mg and Isoniazid 300mg per Capsule	10's Strip/Bottle	30.00

Directions to the Committee for identification of Category II drugs

3724. DR. BAPU KALDATE:
DR. (SHRIMATI) SAROJINI MAHISHI:
SHRI DAYANAND SAHAY:

Will the Minister of INDUSTRY he pleased to state;

(a) whether it is a fact that the Committee for identification of Category II drugs has not annexed any data in respect of sales turn over of drugs considered, monopoly and competitive structure of production, dominance in market share, development of indigenous technologies of drugs etc.;

(b) whether it is also a fact that his Ministry has directed the Committee to annexe complete data in the supplementary report;

(c) if so, when was the communication sent and what are the detarts thereof;

(d) what was the term of reference for extension of tenure of the Committee;

(e) whether it is a fact that apart from identification his Ministry has recently directed the Committee to study the trade commission issue as well as conversion norms; and

(f) if so, when such direction was sent and what are the details of terms of reference?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) No, Sir.

(c) Does not arise.

(d) The term of the Committee has been extended upto 30th September, 1988 to review the representation received by Government regarding discrepancies, anomalies etc. in the list of DPCO, 1987 and to give its recommendations on the same.

(e) and (f) The Committee has been

requested on 21st July, 1988 to examine the trade margin issue.

Amount due on Sulphamethoxazole

3725. SHRI DHARANIDHAR BASU-MATARI: Will the Minister of INDUSTRY be pleased to state:

(a) when did his Ministry write to DPRC/B1CP to allow 8 per cent incidentals on Trimethoprim and Sulphamethoxa-zole;

(b) what is the amount due against Burroughs welcome on Sulphamethoxazole; and

(c) whether the purchase price of Burroughs Wellcome and sale price of the seller for Sulphamethoxazole tally?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) The BICP was requested on 25th November, 1987 (o allow 8 per cent incidentals on Trimethoprim and Sulphamethoxazole.

(b) No amount has been assessed against Burroughs Wellcome on Sulphamefboxa-zole.

(c) The company has not furnished this specific information.

Monitoring the profitability of drug companies

3726. SHRI DHARANIDHAR BASU-MATARI: Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of the drug companies having 80 per cent or more of their products outside price control;

(b) what steps have been taken o monitor the profitability of such companies;

(c) what aspects are monitored by the monitoring cell of his Ministry; and

(d) how can the impact on the public be known without monitoring the sales turn-over?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) To the extent information available only one company M/s. Imar is having more than 80 per ctnt of iheir products outside price control.

(b) As per the provisions of DPCO, 1987, the manufacturers are required to .submit information on prescribed form.

(c) Monitoring cell monitors this price movement of bulk drugs/formulations.

(d) Sales turnover does not give any indication of price.

Production of 6 APA

3727. SHRI CHITTA BASU: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has allowed Penicillin V for the production of 6 APA;

(b) if so, the names of the cormpanies virhich applied for Penicillin V during the last three years upto 31st July, 1988:

(c) what are the names of the companies which have been recommended import licences during this period along with the quantity of penicillin V allowed to be imported in each case;

(d) whether it is a fact that 6 APA is also being produced from penicillin G;

(e) what is the cost of production of penicillin G as per allocation policy and from penicillin V imported and what is the difference;

(f) whether BICP has conducted cost in vestigation in both the cases; and

(g) if so, what are the *names* of the companies the production cost of which was investigated?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) The following companies had applied for import of Penicillin V:

1. M/s. Jagsonpal Pharmaceuticals Ltd.